Immunogenic cell death mediated TLR3/4-activated MSCs in U87 GBM cell line

• Published in: Heliyon Vol. 10; no. 9; p. e29858
• Main Authors: Emami Meybodi, Seyed Mahdi, Moradi Moraddahande, Fateme, Dehghani Firoozabadi, Ali
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 15.05.2024; Elsevier
• Subjects: Cell death; Mesenchymal stem cells; miRSeq; Priming; TLR3; TLR4; Priming; Cell death; TLR4; TLR3; miRSeq; Mesenchymal stem cells
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e29858

Glioblastoma (GBM) is an aggressive primary brain cancer with no promising curative therapies. It has been indicated that MSCs can interact with the tumour microenvironment (TME) through the secretion of soluble mediators regulating intercellular signalling within the TME. TLRs are a multigene family of pattern recognition receptors with evolutionarily conserved regions and are widely expressed in immune and other body cells. MSCs by TLRs can recognize conserved molecular components (DAPMPs and PAPMPs) and activate signalling pathways, which regulate immune and inflammatory responses. MSCs may exert immunomodulatory functions through interaction with their expressed toll-like receptors (TLRs) and exert a protective effect against tumour antigens. As an emerging approach, we aimed to monitor the U87 cell line growth, migration and death markers following specific TLR3/4-primed-MSCs-CMs treatment. We investigated the phenotypic and functional outcomes of primed-CMs and glioma cell line co-culture following short-term, low-dose TLR3/4 priming. The gene expression profile of target genes, including apoptotic markers and related genes, was analyzed by qRT-PCR. MicroRNA-Seq examined the miRNA expression patterns, and flow cytometry evaluated the cell viability and cycle stages. The results showed significant changes in apoptosis and likely necroptosis-related markers following TLR3/4-primed-MSCs-CMs exposure in the glioma cell line. Notably, we observed a considerable induction of selective pro-apoptotic markers and both the early and late stages of apoptosis in treated U87 cell lines. Additionally, the migration rate of glioma cells significantly decreased following MSCs-CM treatment. Our findings confirmed that the exposure of TLR3/4-activated-MSCs-CMs with glioma tumour cells possibly changes the immunogenicity of the tumour microenvironment and induces immunogenic programmed cell death. Our results can support the idea that TLR3/4-primed-MSCs can lead to innate immune-mediated cell death and modify tumour cell biology in invasive and metastatic cancers. •TLR3/4-primed-MSCs-CMs exhibit various properties at different doses and time points.•TLR3/4-primed-MSCs-CMs decrease the viability of the U87 GBM-derived cell line.•Low-dose treatment of TLR3/4 agonists increases glioma cell death and reduces cell migration.•Necroptosis concept as a targeted therapeutic strategy for managing GBM.•Sub-toxic inflammation or para-inflammation as a novel approach in programmed cell death.